503B Outsourcing Facilities Market Global Report 2026

The 503B outsourcing facilities market size has grown rapidly in recent years. It will grow from $5.85 billion in 2025 to $6.48 billion in 2026 at a compound annual growth rate (CAGR) of 10.7%. The growth in the historic period can be attributed to increasing drug shortages within healthcare systems, growing dependence on hospital-based in-house compounding pharmacies, the establishment of the FDA 503B regulatory framework, expansion of hospital networks and centralized procurement systems, and rising demand for sterile injectable medicines in clinical settings.

The 503B outsourcing facilities market size is expected to see rapid growth in the next few years. It will grow to $9.81 billion in 2030 at a compound annual growth rate (CAGR) of 10.9%. The growth in the forecast period can be attributed to the expansion of outpatient infusion and ambulatory care services, rising cost containment pressures across healthcare systems, strengthening regulatory compliance and inspection mandates, increasing emphasis on sterility assurance and quality validation processes, and consolidation among 503B outsourcing facilities and contract manufacturing providers. Major trends in the forecast period include the rising outsourcing of drug shortages to 503B facilities, stricter FDA cGMP compliance requirements and inspection enforcement, growing demand for sterile injectable formulations in hospitals and clinics, increased contracting between hospital group purchasing organizations (GPOs) and outsourcing facilities, and a gradual shift from in-house hospital compounding toward centralized outsourced pharmaceutical production.

The rising number of surgical procedures is expected to drive growth of the 503B outsourcing facilities market in the coming years. Surgical procedures refer to medical operations performed by healthcare professionals to treat, diagnose, or manage diseases, injuries, or medical conditions using manual or instrumental techniques. The increasing volume of surgical procedures is being driven by the rising prevalence of chronic and age-related diseases, which is fueling higher demand for both elective and emergency surgical interventions globally. 503B outsourcing facilities support surgical procedures by providing compounded sterile preparations, including anesthetics, pain management medications, and emergency drugs, which help hospitals and surgical centers maintain a dependable supply of essential medicines for perioperative care. For instance, in April 2025, according to the British Association of Aesthetic Plastic Surgeons, a UK-based professional organization, between 2023 and 2024, cosmetic surgical procedures increased by 5%, reaching a total volume of 27,462 procedures performed in 2024. Therefore, the rising number of surgical procedures is driving the growth of the 503B outsourcing facilities market.

Key companies operating in the 503B outsourcing facilities market are focusing on expanding ready-to-administer sterile injectable portfolios to improve medication availability during shortages, streamline hospital pharmacy workflows, and support critical care treatment requirements. Ready-to-administer sterile injectable portfolios are standardized, pre-prepared sterile medications produced by 503B outsourcing facilities to improve medication safety, reduce preparation time, and ensure a reliable supply of compounded injectable drugs. For example, in December 2024, Pine Pharmaceuticals, a US-based FDA-registered 503B outsourcing facility, announced the launch of norepinephrine 32 mg premix IV bags to expand its hospital-focused product offerings. The newly introduced product was designed to address the limited availability of specific norepinephrine concentrations while supporting customized patient care in healthcare facilities. The company further strengthened its portfolio of ready-to-administer sterile compounds, including critical care medications such as diltiazem HCl, epinephrine, and phenylephrine HCl, reinforcing its commitment to reducing nationwide drug shortages and supporting healthcare providers with cost-effective compounded solutions.

In September 2024, Hims & Hers Health, Inc., a US-based multi-specialty telehealth platform, acquired MedisourceRx for an undisclosed value. Through this acquisition, Hims & Hers intends to strengthen vertical integration across its supply chain and substantially improve its domestic production capabilities for customized, peptide-based therapies to address increasing consumer demand. MedisourceRx is a US-based FDA-registered 503B outsourcing facility focused on manufacturing sterile compounded drug products.

Major companies operating in the 503B outsourcing facilities market are Nephron Pharmaceuticals Corporation, QuVa Pharma Inc., Central Admixture Pharmacy Services Inc. (CAPS), Fagron Sterile Services US, SCA Pharmaceuticals LLC, Leiters Health, Empower Pharmacy LLC, Wells Pharma of Houston LLC, Olympia Pharmaceuticals LLC, Belmar Pharma Solutions LLC, Pine Pharmaceuticals LLC, OSRX Inc., Medivant Healthcare, AnazaoHealth Corporation, Integration Medical (Integradose Compounding Services), Carie Boyd’s Prescription Shop, Exela Pharma Sciences LLC.

North America was the dominant region in the 503B outsourcing facilities market in 2025. Asia-Pacific is expected to be the rapidly expanding region in the forecast period. The regions covered in 503B outsourcing facilities report are Asia-Pacific, South East Asia, Western Europe, Eastern Europe, North America, South America, Middle East, Africa. The countries covered in the 503B outsourcing facilities market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Taiwan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The 503B outsourcing facilities market consists of revenues earned by entities by providing services such as customized medication preparation, batch manufacturing of compounded drugs, hospital pharmacy outsourcing, and ready-to-administer injectable preparation. The market value includes the value of related goods sold by the service provider or included within the service offering. Only goods and services traded between entities or sold to end consumers are included.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

The 503B outsourcing facilities market research report is one of a series of new reports that provides 503B outsourcing facilities market statistics, including 503B outsourcing facilities industry global market size, regional shares, competitors with a 503B outsourcing facilities market share, detailed 503B outsourcing facilities market segments, market trends and opportunities, and any further data you may need to thrive in the 503B outsourcing facilities industry. This 503B outsourcing facilities market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

This product will be delivered within 1-3 business days.